Strominnate Therapeutics targets challenging tumors like Glioblastoma multiforme (GBM), the most prevalent and aggressive brain tumor affecting adults. Current treatment consists of surgery, radiation therapy, and chemotherapy, but unfortunately, there exists no effective cure for GBM yet. Furthermore, GBM does not respond to immunotherapy either. The company develops innovative solutions for tumors like GBM that do not respond to treatments so that they become sensitive to immunotherapies. Strominnate Therapeutics´s approach is based on their unique know-how and protected use of a new immune cell with anti-tumor and immunomodulatory properties, stroma microglia.
Tania Ramos-Moreno is the founder and CEO of Strominnate Therapeutics AB, that is based on her research at the Stem Cell Center in Lund University. She holds a PhD in Neuroscience and brings an extensive background on cell and gene therapies for treating disease and tumor in the central nervous system (CNS). She has characterized and discovered the immune cell that the company uses for treating brain tumors, and brings experience on leading international groups in diverse academic environments.
Did you know?
Strominnate Therapeutics was founded by a Spanish female researcher.